FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025903047> ?p ?o ?g. }

• W3025903047 endingPage "1190" @default.
• W3025903047 startingPage "1181" @default.
• W3025903047 abstract "Abstract Background Effects of CYP2C19 polymorphism on voriconazole concentration (C 0 ), dose‐adjusted trough concentrations (C 0 /dose) and voriconazole‐to‐voriconazole‐N‐oxide concentration ratio (C 0 /C N ) have not been fully investigated. Objectives To investigate correlations of CYP2C19 polymorphisms with plasma concentrations of voriconazole and the major metabolite voriconazole‐N‐oxide in elderly patients. Methods A prospective, multi‐centre, non‐intervention, open clinical study was conducted within Southwestern Chinese patients clinically diagnosed with invasive fungal infections, to investigate the associations of CYP2C19∗2 (681G > A), CYP2C19∗3 (636G > A) and CYP2C19∗17 (−806C > T) genetic polymorphisms with voriconazole C 0 , C 0 /dose and C 0 /C N . Results The study included 131 adult patients, of which 72 were elderly (≥60 years) and 59 were adults (<60 years). The allele frequencies of CYP2C19∗2 , ∗3 and ∗17 in the elderly cohort were 61.1%, 29.9% and 7.6%, respectively, which were similar to those in the adult cohort (66.9%, 29.7% and 2.5%, respectively; P > .05). The median voriconazole C 0 (C 0 ), C 0 /dose and C 0 /C N ratio in patients with the CYP2C19∗1/∗2 and CYP2C19∗2/∗2 genotypes were significantly higher than those in patients with the CYP2C19∗1/∗1 genotype in the adult cohort ( P < .05). The C 0 and C 0 /dose in patients with the CYP2C19∗1/∗3 and CYP2C19∗2/∗2 genotypes, and the C 0 /C N ratio for patients with the CYP2C19∗1/∗2 genotype were numerically higher than those in patients with the CYP2C19∗1/∗1 genotype in the elderly cohort, but this difference was not statistically significant ( P > 0.05). The C 0 , C 0 /dose and C 0 /C N in patients with poor metaboliser phenotypes were higher than in those with normal metaboliser phenotypes and C 0 in patients with intermediate metaboliser phenotypes were significantly higher than in those with normal metaboliser phenotypes in the adult cohort ( P < .05). However, there were no significant differences in the C 0 , C 0 /dose and C 0 /C N among different CYP2C19‐predicted metabolic phenotypes in the elderly cohort. Conclusions Voriconazole C 0 , C 0 /dose and C 0 /C N ratio are not significantly affected by the CYP2C19∗2 / ∗3 polymorphisms in the elderly patients." @default.
• W3025903047 created "2020-05-21" @default.
• W3025903047 creator A5006670665 @default.
• W3025903047 creator A5020502401 @default.
• W3025903047 creator A5029757714 @default.
• W3025903047 creator A5046676286 @default.
• W3025903047 creator A5071214162 @default.
• W3025903047 creator A5082020327 @default.
• W3025903047 creator A5088424842 @default.
• W3025903047 date "2020-09-12" @default.
• W3025903047 modified "2023-10-06" @default.
• W3025903047 title "Effect of<i>CYP2C19</i>polymorphism on the plasma voriconazole concentration and voriconazole‐to‐voriconazole‐N‐oxide concentration ratio in elderly patients" @default.
• W3025903047 cites W1499560017 @default.
• W3025903047 cites W1965270391 @default.
• W3025903047 cites W1985282417 @default.
• W3025903047 cites W1992995027 @default.
• W3025903047 cites W1996806440 @default.
• W3025903047 cites W1999331179 @default.
• W3025903047 cites W2015870178 @default.
• W3025903047 cites W2016465981 @default.
• W3025903047 cites W2022104878 @default.
• W3025903047 cites W2031785695 @default.
• W3025903047 cites W2036323185 @default.
• W3025903047 cites W2048111050 @default.
• W3025903047 cites W2051665742 @default.
• W3025903047 cites W2071524497 @default.
• W3025903047 cites W2076522986 @default.
• W3025903047 cites W2076572003 @default.
• W3025903047 cites W2083239316 @default.
• W3025903047 cites W2085196027 @default.
• W3025903047 cites W2088294854 @default.
• W3025903047 cites W2092839327 @default.
• W3025903047 cites W2116635252 @default.
• W3025903047 cites W2146753629 @default.
• W3025903047 cites W2158172729 @default.
• W3025903047 cites W2196792053 @default.
• W3025903047 cites W2216117396 @default.
• W3025903047 cites W2219492003 @default.
• W3025903047 cites W2284211524 @default.
• W3025903047 cites W2335550074 @default.
• W3025903047 cites W2400119402 @default.
• W3025903047 cites W2470291098 @default.
• W3025903047 cites W2508431504 @default.
• W3025903047 cites W2562778159 @default.
• W3025903047 cites W2746634391 @default.
• W3025903047 cites W2898258916 @default.
• W3025903047 cites W2902026336 @default.
• W3025903047 cites W2902449467 @default.
• W3025903047 cites W2910180756 @default.
• W3025903047 cites W2911287033 @default.
• W3025903047 cites W2968743087 @default.
• W3025903047 cites W2995093969 @default.
• W3025903047 cites W3163546726 @default.
• W3025903047 doi "https://doi.org/10.1111/myc.13105" @default.
• W3025903047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32416606" @default.
• W3025903047 hasPublicationYear "2020" @default.
• W3025903047 type Work @default.
• W3025903047 sameAs 3025903047 @default.
• W3025903047 citedByCount "9" @default.
• W3025903047 countsByYear W30259030472021 @default.
• W3025903047 countsByYear W30259030472022 @default.
• W3025903047 countsByYear W30259030472023 @default.
• W3025903047 crossrefType "journal-article" @default.
• W3025903047 hasAuthorship W3025903047A5006670665 @default.
• W3025903047 hasAuthorship W3025903047A5020502401 @default.
• W3025903047 hasAuthorship W3025903047A5029757714 @default.
• W3025903047 hasAuthorship W3025903047A5046676286 @default.
• W3025903047 hasAuthorship W3025903047A5071214162 @default.
• W3025903047 hasAuthorship W3025903047A5082020327 @default.
• W3025903047 hasAuthorship W3025903047A5088424842 @default.
• W3025903047 hasConcept C104317684 @default.
• W3025903047 hasConcept C112705442 @default.
• W3025903047 hasConcept C126322002 @default.
• W3025903047 hasConcept C135763542 @default.
• W3025903047 hasConcept C140840227 @default.
• W3025903047 hasConcept C16005928 @default.
• W3025903047 hasConcept C2779548794 @default.
• W3025903047 hasConcept C2780690907 @default.
• W3025903047 hasConcept C2910800852 @default.
• W3025903047 hasConcept C526171541 @default.
• W3025903047 hasConcept C54355233 @default.
• W3025903047 hasConcept C62231903 @default.
• W3025903047 hasConcept C71924100 @default.
• W3025903047 hasConcept C72563966 @default.
• W3025903047 hasConcept C86803240 @default.
• W3025903047 hasConcept C90924648 @default.
• W3025903047 hasConcept C98274493 @default.
• W3025903047 hasConceptScore W3025903047C104317684 @default.
• W3025903047 hasConceptScore W3025903047C112705442 @default.
• W3025903047 hasConceptScore W3025903047C126322002 @default.
• W3025903047 hasConceptScore W3025903047C135763542 @default.
• W3025903047 hasConceptScore W3025903047C140840227 @default.
• W3025903047 hasConceptScore W3025903047C16005928 @default.
• W3025903047 hasConceptScore W3025903047C2779548794 @default.
• W3025903047 hasConceptScore W3025903047C2780690907 @default.
• W3025903047 hasConceptScore W3025903047C2910800852 @default.
• W3025903047 hasConceptScore W3025903047C526171541 @default.
• W3025903047 hasConceptScore W3025903047C54355233 @default.

• next